Posts

Showing posts with the label Major Depressive Disorder (MDD) market outlook

Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Major Depressive Disorder (MDD) Market Outlook Thelansis’s “Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder (MDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Major Depressive Disorder (MDD) Market Outlook Thelansis’s “Major Depressive Disorder (MDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder (MDD)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Major Depressive Disorder (MDD) Overview Major Depressive Disorder (MDD) is a common and serious psychiatric condition characterized by persistent low mood, loss of interest or pleasure in daily activities, and functional impairment lasting at least two weeks. It affects individuals across all age groups and arises from a complex interplay of genetic, neurobiological, psychological, and environmental fa...

Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Major depressive disorder (MDD), also known as Depression, is a severe medical condition that disrupts various aspects of a person's life, including mood, behavior, thought processes, and physical well-being. While sadness and grief are normal responses to life's challenges, depression represents a more intense and prolonged state of emotional distress. There are also other related conditions, such as bipolar disorder (manic-depressive illness) and dysthymia. Bipolar disorder is characterized by alternating episodes of depression and mania. During manic episodes, individuals may experience extreme and inappropriate "high" emotions that can lead to risky and destructive behaviors. Dysthymia, on the other hand, exhibits symptoms similar to those of major depressive disorder but typically persists over a longer duration. The decline in hippocampal function is believed to play a role in depression by inhibiting the hypothalamic-pituitary-adrenal (HPA) axis, potentially c...

Major Depressive Disorder (MDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Major depressive disorder (MDD), also referred to as depression, is a severe medical illness that disrupts a person’s mood, behavior, thought processes, and physical health. Sadness and grief are normal reactions to life stresses. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The decline in hippocampal function, which is believed to have an inhibitory effect on the hypothalamic-pituitary-adrenal (HPA) axis, could potentially be responsible for the hypercortisolemia seen in depression. Pro-inflammatory marker levels are reported to be elevated in depressed patients, such as C-reactive protein (CRP), interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α). ·     ...